Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Brett King, James V. Cassella, Charles Lynde et al.|Journal of the American Academy of Dermatology|2024

Cited by 79